Takao Kobayashi

OBJECTIVE: To evaluate the efficacy and safety of the estetrol (E4) (15 mg)/drospirenone (DRSP) (3 mg) combination in a cyclic regimen in Japanese women with primary and secondary dysmenorrhea. DESIGN: A 16-week, multicenter, randomized, d…

OBJECTIVE: To study the impact of estetrol (E4), a novel native estrogen with selective tissue activity, on endometriosis-associated pelvic pain (EAPP) and global impressions of endometriosis pain. DESIGN: Multicenter, randomized, open-lab…

PURPOSE: To clarify the efficacy and safety of the estetrol 15 mg/drospirenone 3 mg combination among Japanese women with adenomyosis by post hoc analyses of a previous randomized clinical study. METHODS: Post hoc analyses were performed u…

At our hospital, we have incrementally expanded the indications for total laparoscopic hysterectomy (TLH) since its introduction in 2019. We report on our experience with a patient who had TLH for a cervical fibroid complicated by endometri…

OBJECTIVE: To evaluate the efficacy and safety of 24-week cyclic administration of estetrol (E4) (15 mg)/drospirenone (DRSP) (3 mg) in Japanese patients with endometriosis. DESIGN: A 24-week, multicenter, randomized, double-blind, placebo-…

Venous thromboembolism is a serious safety concern in women using combined oral contraceptives; ethinyl estradiol (EE) is widely used as an estrogen. Estetrol (E4) is a native estrogen with selective tissue activity and exclusively produced…

ObjectiveThe aim of this study is to estimate the risk of thromboembolism related to body mass index (BMI) and aging among users of hormonal contraceptives in Japan.MethodsA case-control study of the risk of obesity and a descriptive study …